Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B458fe4246ece06ccb5f79b59d50ff211> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B458fe4246ece06ccb5f79b59d50ff211 NCIT_P378 "NCI" @default.
- B458fe4246ece06ccb5f79b59d50ff211 type Axiom @default.
- B458fe4246ece06ccb5f79b59d50ff211 annotatedProperty IAO_0000115 @default.
- B458fe4246ece06ccb5f79b59d50ff211 annotatedSource NCIT_C102554 @default.
- B458fe4246ece06ccb5f79b59d50ff211 annotatedTarget "An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells." @default.